Immunology and Infection
A subscription to JoVE is required to view this content.
You will only be able to see the first 20 seconds.
Summary October 5th, 2015
The goal of this protocol is to manufacture pathogen-specific clinical-grade T cells using a bench-top, automated, second generation cell enrichment device that incorporates a closed cytokine capture system and does not require dedicated staff or use of a GMP facility. The cytomegalovirus pp65-specific-T cells generated can be directly administered to patients.